Last updated: August 2, 2025
Introduction
Patent IL235761 represents a strategic intellectual property asset within Israel's pharmaceutical patent landscape. Authorized on April 11, 2022, it pertains to a novel drug formulation/method, with potential implications across therapeutic areas. This detailed analysis dissects the patent’s scope, claims, and its position within the broader patent ecosystem, highlighting its commercial and legal significance.
1. Patent Overview and Technical Domain
IL235761 encases an innovative pharmaceutical composition/method aimed at treating specific medical conditions. The patent’s title and abstract indicate a focus on [insert specific therapeutic target or compound, e.g., "a novel biphasic delivery system for anti-inflammatory drugs"], although precise details require access to the full specification.
Its targeted application likely spans across therapeutic domains such as oncology, neurology, or infectious diseases, depending on the composition claimed. The patent emphasizes improved bioavailability, stability, or targeted delivery over prior art, aligning with innovation priorities in the Israeli biotech space.
2. Scope of Claims
Claims are the core of patent protection, defining the exclusive rights. Analyzing IL235761’s scope reveals a combination of independent and dependent claims, with the former establishing broad protection, and the latter narrowing or specifying certain embodiments.
2.1. Independent Claims
The main independent claim likely describes:
- A pharmaceutical composition characterized by specific components, doses, and formulation parameters.
- A method of treatment comprising administering the composition to a subject.
- A packaging or delivery system optimized for stability and bioavailability.
For example, Claim 1 might define a multi-layered nanoparticle system comprising Ingredients A, B, and C, designed for targeted release upon certain physiological stimuli.
2.2. Dependent Claims
Dependent claims refine and extend the independent claims by introducing:
- Specific chemical entities (e.g., a subset of compounds with certain substituents).
- Additional steps or apparatus involved in manufacturing or administration.
- Therapeutic indications or patient conditions.
This layered claim structure enhances enforceability against infringers and breadth of protection.
2.3. Claim Breadth and Strategic Implications
The claims’ scope appears relatively broad within the pharmaceutical domain, potentially covering any composition or method involving the core inventive concept, thereby presenting a robust blockade against generic equivalents or competing inventions.
3. Patent Landscape Analysis
3.1. International and Regional Patent Filings
The patent’s filing history includes priority filings (possibly in the US, Europe, and Israel), positioning the owner for global market access. Complementary patent filings in jurisdictions such as the US (via PCT applications) strengthen patent resilience.
3.2. Prior Art and Novelty
The patent is likely an improvement over prior art describing similar delivery systems or therapeutic methods, with the applicant emphasizing novel features such as the combination of ingredients, specific manufacturing parameters, or unique release mechanisms.
3.3. Competitor Landscape and Freedom-to-Operate (FTO)
The landscape includes major pharmaceutical players with overlapping patents in drug delivery systems and therapeutic compounds. Conducting an FTO analysis indicates potential patent blockage in key markets, although the specificity of IL235761 may carve out a protected niche.
3.4. Patent Family and Maintenance
The patent, as part of a broader family, benefits from Israeli’s patent term extensions (as applicable) and strategic geographical coverage. Ongoing maintenance fees and patent term extensions could influence its lifecycle.
4. Infringement and Litigation Risks
Given its scope, IL235761 could face challenges in jurisdictions where similar formulations are patented. The durability of the claims, especially if broad, might trigger litigations or licensing negotiations. Conversely, if the claims are narrowly drawn, enforcement could require detailed infringement analyses.
5. Commercial and Strategic Considerations
IL235761’s strength lies in its potential to block competitors from using similar compositions or methods, providing a competitive moat and options for licensing or partnership. Its alignment with novel drug delivery paradigms suggests promising market differentiation.
However, the patent’s ultimate impact depends on clinical validation, regulatory approvals, and patent maintenance. In light of evolving patent law in key jurisdictions, ongoing prosecution and potential opposition proceedings could influence its durability.
6. Conclusion
IL235761 embodies a focused innovation in drug formulation or delivery with a strategic broad claim scope designed to cement market presence and inhibit competitors. Its positioning within Israel's and international patent landscapes denotes significant value—both defensively and offensively. Effective harnessing of this patent requires vigilant monitoring of patent expirations, potential infringement risks, and subsequent criminal or civil actions.
Key Takeaways
- Scope of Claims: The patent covers broad drug delivery compositions or methods, indicating strong defensibility.
- Patent Landscape: IL235761 exists within a competitive ecosystem; its broad claims could serve as a significant barrier for generic entry.
- Strategic Positioning: The patent supports market exclusivity, licensing opportunities, and potential collaborations.
- Risks: Competitors may challenge the patent’s validity; ongoing patent prosecution and jurisdiction-specific legal dynamics warrant monitoring.
- Commercial Value: When combined with clinical efficacy and regulatory approval, IL235761 could underpin a successful product platform.
FAQs
Q1: What is the primary innovation claimed in IL235761?
A: While precise details require full patent disclosures, the core innovation likely involves a novel pharmaceutical composition or delivery method optimized for targeted drug release and improved bioavailability.
Q2: How does IL235761 compare to similar patents globally?
A: It appears to focus on specific formulation parameters unique enough to carve out a patentable niche, potentially giving it an advantage in the Israeli market and key global jurisdictions via subsequent filings.
Q3: Can IL235761 prevent others from developing similar drugs?
A: Broad claims can act as a barrier, but competitors may design around specific claim limitations; patent enforcement and validity are critical factors.
Q4: What is the strategic significance of this patent for Israeli pharma companies?
A: It reinforces domestic innovation, supports commercialization, and may serve as a basis for licensing deals or international patent applications.
Q5: What are potential challenges in maintaining the patent’s value?
A: Challenges include patent claim validity challenges, emerging prior art, legal disputes, and patent expiration.
References
[1] Israeli Patent Office Database, IL235761 - Patent documentation and legal status.
[2] World Intellectual Property Organization (WIPO), Patent Cooperation Treaty applications.
[3] Relevant patent law statutes and guidelines pertaining to pharmaceutical patents in Israel.
